← Leaderboards
Shaoguang Li
Univ Of Massachusetts Med Sch Worcester
$10,655,005
Attributed
$10,655,005
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,655,005 · 7
By mechanism
R01$9,812,467 · 5
R21$842,538 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsAffectLeukemiaSignal TransductionMolecularKnockout MiceCellsFoundationsLeukemic CellLinkPlayNovel TherapeuticsStem CellsGenesPreventKinase InhibitorIn VitroHuman DiseaseBcr-Abl Fusion ProteinsMalignant NeoplasmsCell SurvivalSolidGeneticImatinib
Grant awards (30)
Targeting cancer stem cells in JAK2V617F induced neoplasm$509,492
R01 · FY2024 · CA · contact PI
Targeting cancer stem cells in JAK2V617F induced neoplasm$525,580
R01 · FY2023 · CA · contact PI
Targeting cancer stem cells in JAK2V617F induced neoplasm$525,580
R01 · FY2022 · CA · contact PI
Developing a novel therapeutic strategy for overcoming TKI resistance in ALL$478,090
R01 · FY2022 · CA · contact PI
Targeting cancer stem cells in JAK2V617F induced neoplasm$536,307
R01 · FY2021 · CA · contact PI
Developing a novel therapeutic strategy for overcoming TKI resistance in ALL$487,847
R01 · FY2021 · CA · contact PI
Targeting cancer stem cells in JAK2V617F induced neoplasm$536,307
R01 · FY2020 · CA · contact PI
Developing a novel therapeutic strategy for overcoming TKI resistance in ALL$487,847
R01 · FY2020 · CA · contact PI
Developing a novel therapeutic strategy for overcoming TKI resistance in ALL$473,211
R01 · FY2019 · CA · contact PI
A novel genetic pathway for survival of B-lymphoblastic leukemia-initiating cells$176,690
R21 · FY2019 · CA · contact PI
Developing a novel therapeutic strategy for overcoming TKI resistance in ALL$487,847
R01 · FY2018 · CA · contact PI
Zileuton as a chemopreventive agent for chronic myeloid leukemia$347,563
R01 · FY2018 · CA · contact PI
A novel genetic pathway for survival of B-lymphoblastic leukemia-initiating cells$218,588
R21 · FY2018 · CA · contact PI
Zileuton as a chemopreventive agent for chronic myeloid leukemia$347,563
R01 · FY2017 · CA · contact PI
Zileuton as a chemopreventive agent for chronic myeloid leukemia$347,563
R01 · FY2016 · CA · contact PI
Zileuton as a chemopreventive agent for chronic myeloid leukemia$347,563
R01 · FY2015 · CA · contact PI
Zileuton as a chemopreventive agent for chronic myeloid leukemia$347,563
R01 · FY2014 · CA · contact PI
Identification of novel target genes for polycythemia vera (PV)$198,135
R21 · FY2013 · HL · contact PI
Identification of novel target genes for polycythemia vera (PV)$249,125
R21 · FY2012 · HL · contact PI
Survival Mechanisms of Cancer-initiating (Stem) Cells in Ph+ Leukemia$303,174
R01 · FY2011 · CA · contact PI
Survival Mechanisms of Cancer-initiating (Stem) Cells in Ph+ Leukemia$312,550
R01 · FY2010 · CA · contact PI
Survival Mechanisms of Cancer-initiating (Stem) Cells in Ph+ Leukemia$311,679
R01 · FY2009 · CA · contact PI
Src Kinases in Ph+ Lymphoblastic Leukemia$276,123
R01 · FY2009 · CA · contact PI
Survival Mechanisms of Cancer-initiating (Stem) Cells in Ph+ Leukemia$310,729
R01 · FY2008 · CA · contact PI
Src Kinases in Ph+ Lymphoblastic Leukemia$284,832
R01 · FY2008 · CA · contact PI
Survival Mechanisms of Cancer-initiating (Stem) Cells in Ph+ Leukemia$19,871
R01 · FY2008 · CA · contact PI
Survival Mechanisms of Cancer-initiating (Stem) Cells in Ph+ Leukemia$329,017
R01 · FY2007 · CA · contact PI
Src Kinases in Ph+ Lymphoblastic Leukemia$284,832
R01 · FY2007 · CA · contact PI
Src Kinases in Ph+ Lymphoblastic Leukemia$293,339
R01 · FY2006 · CA · contact PI
Src Kinases in Ph+ Lymphoblastic Leukemia$300,398
R01 · FY2005 · CA